Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: April 18, 2012
Reporting Period: First Quarter 2012
This filing announces the results of operations for the first quarter of 2012. The detailed financial data is contained in a press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly states that the press release (Exhibit 99.1) contains the results, including both GAAP and non-GAAP measures.
Non-GAAP Adjustments Mentioned: The company utilizes non-GAAP measures that adjust for:
- Acquisition-related costs
- Separation costs
- Milestone payments
- Litigation reserves
- Acquired in-process research and development
- Restructuring and cost reduction initiatives
- Effects of the change in the calendar year-end for international operations
Material Changes
The filing text does not provide specific comparative data or quantify material changes versus the prior comparable period. Investors must refer to the incorporated press release for year-over-year performance analysis.
Guidance, Outlook, and Management Commentary
Management Commentary: Abbott's management believes the presentation of non-GAAP financial measures provides useful information to investors regarding ongoing business performance and is used internally to monitor business performance. However, management cautions that these measures should be considered in addition to, and not as a substitute for, GAAP financial measures.
Guidance and Risks: The provided text does not contain specific forward-looking guidance, risk factors, or contingencies beyond the general caution regarding non-GAAP measures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q1 2012 revenue, net earnings, and diluted earnings per share figures.
- Verify the reconciliation between GAAP and non-GAAP financial measures to understand the impact of acquisition costs, restructuring, and litigation reserves.
- Assess the impact of the change in the calendar year-end for international operations on the reported results.
- Confirm whether the "specified items" excluded from non-GAAP measures are expected to recur in future periods.